reprofiled Src inhibitors (Fratagene Therapeutics)

N/A

Report date: 2025/01/26 16:51:44
NME

Base Information

Drug Namereprofiled Src inhibitors (Fratagene Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase SRC inhibitorsFrataxin, mitochondrial stimulants
TargetsFrataxin, mitochondrialTyrosine-protein kinase SRC
Therapy Area/IndicationsFriedreich Ataxia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIreland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFratagene Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFratagene Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsFriedreich Ataxia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A